NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor

Article English OPEN
Galvani, Elena ; Sun, Jing ; Leon, Leticia G. ; Sciarrillo, Rocco ; Narayan, Ravi S. ; Tjin Tham Sjin, Robert ; Lee, Kwangho ; Ohashi, Kadoaki ; Heideman, Daniëlle A.M. ; Alfieri, Roberta R. ; Heynen, Guus J. ; Bernards, René ; Smit, Egbert F. ; Pao, William ; Peters, Godefridus J. ; Giovannetti, Elisa (2015)
  • Publisher: Impact Journals LLC
  • Journal: Oncotarget, volume 6, issue 40, pages 42,717-42,732 (eissn: 1949-2553)
  • Related identifiers: pmc: PMC4767465
  • Subject: NF-κB | EGFR-T790M | NSCLC | drug-resistance | Research Paper | EMT
    mesheuropmc: respiratory tract diseases

The clinical efficacy of EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations is limited by the emergence of acquired resistance, mostly ascribed to the secondary EGFR-T790M mutation. Selective EGFR-T790M inhi... View more